{"drugs":["Floxin","Ocuflox","Ofloxacin"],"mono":[{"id":"420450-s-0","title":"Generic Names","mono":"Ofloxacin"},{"id":"420450-s-1","title":"Dosing and Indications","sub":[{"id":"420450-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acute bacterial exacerbation of chronic bronchitis:<\/b> 400 mg ORALLY every 12 hours for 10 days<\/li><li><b>Bacterial conjunctivitis:<\/b> 0.3% ophthalmic solution, instill 1 or 2 drops in affected eye(s) every 2 to 4 hours for 2 days, then 1 to 2 drops 4 times daily on days 3 through 7<\/li><li><b>Chlamydial infection:<\/b> 300 mg ORALLY every 12 hours daily for 7 days<\/li><li><b>Chronic purulent otitis media - Perforation of tympanic membrane:<\/b> (otic solution) 10 drops into affected ear(s) twice daily for 14 days<\/li><li><b>Community acquired pneumonia:<\/b> 400 mg ORALLY every 12 hours for 10 days<\/li><li><b>Corneal ulcer:<\/b> (0.3% ophthalmic solution) days 1 and 2, instill 1 to 2 drops in affected eye(s) every 30 minutes while awake, and awaken to instill 1 to 2 drops at approximately 4 and 6 hours after going to bed; days 3 to 7, instill 1 to 2 drops hourly while awake; days 7 to 9, through treatment completion, instill 1 to 2 drops 4 times daily<\/li><li><b>Cystitis, Uncomplicated:<\/b> (due to E coli or K pneumoniae) 200 mg ORALLY every 12 hours for 3 days<\/li><li><b>Cystitis, Uncomplicated:<\/b> (due to other susceptible organisms) 200 mg ORALLY every 12 hours for 7 days<\/li><li><b>Epididymitis:<\/b> (caused by enteric organisms, or with negative gonococcal nucleic acid amplification test) 300 mg ORALLY twice daily for 10 days<\/li><li><b>Gonorrhea:<\/b> uncomplicated, 400 mg ORALLY as a single dose; fluoroquinolones are no longer recommended by the CDC in the United States for the treatment of gonorrhea<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated:<\/b> 400 mg ORALLY every 12 hours for 10 days<\/li><li><b>Nongonococcal urethritis:<\/b> 300 mg ORALLY twice daily for 7 days<\/li><li><b>Otitis externa:<\/b> (otic solution) 10 drops into affected ear(s) once daily for 7 days<\/li><li><b>Pelvic inflammatory disease:<\/b> 400 mg ORALLY every 12 hours for 10 to 14 days with or without metronidazole 500 mg ORALLY twice daily for 14 days; however, fluoroquinolones are no longer recommended by the CDC in the United States for the treatment of pelvic inflammatory disease<\/li><li><b>Prostatitis:<\/b> 300 mg ORALLY every 12 hours for 6 weeks<\/li><li><b>Traveler's diarrhea:<\/b> 300 mg ORALLY twice daily for 1 to 3 days<\/li><li><b>Urinary tract infectious disease, Complicated:<\/b> 200 mg ORALLY every 12 hours for 10 days<\/li><\/ul>"},{"id":"420450-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy in children less than 18 years of age have not been established (oral)<\/li><li><b>Acute otitis media - Tympanostomy:<\/b> (Otic solution) 1 to 12 years of age, 5 drops in affected ear(s) twice daily for 10 days<\/li><li><b>Bacterial conjunctivitis:<\/b> (1 year or older) 0.3% ophthalmic solution, instill 1 or 2 drops in affected eye(s) every 2 to 4 hours for 2 days, then 1 to 2 drops 4 times daily on days 3 through 7<\/li><li><b>Chronic purulent otitis media - Perforation of tympanic membrane:<\/b> (otic solution; 12 years and older) 10 drops in affected ear(s) twice daily for 14 days<\/li><li><b>Corneal ulcer:<\/b> (0.3% ophthalmic solution; 1 year or older) days 1 and 2, instill 1 to 2 drops in affected eye(s) every 30 minutes while awake, and awaken to instill 1 to 2 drops at approximately 4 and 6 hours after going to bed; days 3 to 7, instill 1 to 2 drops hourly while awake; days 7 to 9, through treatment completion, instill 1 to 2 drops 4 times daily<\/li><li><b>Otitis externa:<\/b> (otic solution; 6 mo to 13 years of age) 5 drops in affected ear(s) once daily for 7 days<\/li><li><b>Otitis externa:<\/b> (otic solution; 13 years and older) 10 drops into affected ear(s) once daily for 7 days<\/li><\/ul>"},{"id":"420450-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> (oral) CrCl 20 to 50 mL\/min, usual dose every 24 hours; CrCl less than 20 mL\/min, one-half the usual dose every 24 hours<\/li><li><b>hepatic impairment:<\/b> (oral) severe hepatic impairment (cirrhosis), maximum of 400 mg every 24 hours<\/li><\/ul>"},{"id":"420450-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute bacterial exacerbation of chronic bronchitis<\/li><li>Acute otitis media - Tympanostomy<\/li><li>Bacterial conjunctivitis<\/li><li>Chlamydial infection<\/li><li>Chronic purulent otitis media - Perforation of tympanic membrane<\/li><li>Community acquired pneumonia<\/li><li>Corneal ulcer<\/li><li>Cystitis, Uncomplicated<\/li><li>Gonorrhea<\/li><li>Infection due to Staphylococcus aureus<\/li><li>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated<\/li><li>Nongonococcal urethritis<\/li><li>Otitis externa<\/li><li>Pelvic inflammatory disease<\/li><li>Prostatitis<\/li><li>Urinary tract infectious disease, Complicated<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Acute salpingitis<\/li><li>Bacterial infectious disease; Prophylaxis<\/li><li>Epididymitis<\/li><li>Febrile neutropenia<\/li><li>Helicobacter pylori gastrointestinal tract infection<\/li><li>Infection due to Mycobacterium fortuitum<\/li><li>Infection of bone - Infectious disorder of joint<\/li><li>Infective cholangitis<\/li><li>Leprosy<\/li><li>Pyelonephritis<\/li><li>Q fever<\/li><li>Sepsis<\/li><li>Surgical procedure; Prophylaxis<\/li><li>Traveler's diarrhea<\/li><li>Tuberculosis<\/li><li>Typhoid fever<\/li><li>Upper respiratory infection<\/li><\/ul>"}]},{"id":"420450-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Fluoroquinolones, including ofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. Risk further increases with age over 60 years, concomitant steroid therapy, and kidney, heart, or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis.<br\/>"},{"id":"420450-s-3","title":"Contraindications\/Warnings","sub":[{"id":"420450-s-3-9","title":"Contraindications","mono":"hypersensitivity to ofloxacin, levofloxacin or any other quinolone <br\/>"},{"id":"420450-s-3-10","title":"Precautions","mono":"<ul><li>myasthenia gravis; may exacerbate muscle weakness; ventilatory support requirement and death have been reported; avoid use<\/li><li>tendinitis and tendon rupture, increased risk (oral only); risk further increases with age over 60 years, concomitant steroid therapy, and kidney, heart or lung transplant; discontinue therapy at first sign of tendon pain, swelling or inflammation<\/li><li>central nervous system disorders, known or suspected; may predispose patient to seizures or lower seizure threshold<\/li><li>coadministration with Class IA (eg, procainamide, quinidine) or Class III (eg, amiodarone, sotalol) antiarrhythmic agents should be avoided<\/li><li>diabetic patients, especially patients receiving oral hypoglycemic agents or insulin; may cause hyperglycemia or hypoglycemia; discontinue if hypoglycemia occurs<\/li><li>excessive sunlight; risk for phototoxic reactions<\/li><li>hepatic impairment\/insufficiency; elimination may be reduced<\/li><li>hypersensitivity, including serious or fatal reactions, has occurred; may include cardiovascular collapse, hypotension, seizure, acute respiratory distress, and serious skin reactions<\/li><li>pediatric patients; safety and efficacy not established<\/li><li>peripheral neuropathy has been reported with oral and injectable fluoroquinolones; may occur any time during therapy and persist for months to years or become permanent even after discontinuation; if symptoms occur, discontinue use and switch to a non-fluoroquinolone unless benefit outweighs risk<\/li><li>physical activity, strenuous; may increase risk of tendon rupture<\/li><li>pregnancy, nursing mothers; safety and efficacy not established<\/li><li>proarrhythmic conditions such as uncorrected hypokalemia or prolonged of the QTc interval; increased risk for ventricular arrhythmias and\/or torsades de pointes; use not recommended<\/li><li>renal failure; may increase risk of tendon rupture<\/li><li>renal impairment\/insufficiency (creatinine clearance rate of 50 mL\/minute or less); increased risk of seizure; dosage adjustment recommended<\/li><li>tendon disorders, such as rheumatoid arthritis, history of; may increase risk of tendon rupture<\/li><\/ul>"},{"id":"420450-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"420450-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},{"id":"420450-s-4","title":"Drug Interactions","sub":[{"id":"420450-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"420450-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Acecainide (theoretical)<\/li><li>Acetohexamide (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Alosetron (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Benfluorex (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Droperidol (probable)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Exenatide (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gliclazide (theoretical)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Gliquidone (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Insulin (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Bovine (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Moricizine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rasagiline (established)<\/li><li>Repaglinide (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (probable)<\/li><\/ul>"},{"id":"420450-s-4-15","title":"Moderate","mono":"<ul><li>Betamethasone (established)<\/li><li>Budesonide (established)<\/li><li>Corticotropin (established)<\/li><li>Cortisone (established)<\/li><li>Cosyntropin (established)<\/li><li>Deflazacort (established)<\/li><li>Dexamethasone (established)<\/li><li>Didanosine (probable)<\/li><li>Fludrocortisone (established)<\/li><li>Fluocortolone (established)<\/li><li>Hydrocortisone (established)<\/li><li>Iron (probable)<\/li><li>Lanthanum Carbonate (probable)<\/li><li>Methylprednisolone (established)<\/li><li>Prednisolone (established)<\/li><li>Prednisone (established)<\/li><li>Sucralfate (probable)<\/li><li>Triamcinolone (established)<\/li><li>Zinc (probable)<\/li><\/ul>"}]},{"id":"420450-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus (1%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (1%), Nausea (3%), Vomiting (1%)<\/li><li><b>Neurologic:<\/b>Dizziness (1%), Headache (1%), Insomnia (3%)<\/li><li><b>Ophthalmic:<\/b>Burning sensation in eye, Pain in eye<\/li><li><b>Reproductive:<\/b>Pruritus of genital organs, Female (1%), Vaginitis (1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest (less than 1%), Prolonged QT interval, Torsades de pointes, Vasculitis (less than 1%)<\/li><li><b>Dermatologic:<\/b>Phototoxicity, Rash (1%), Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Endocrine metabolic:<\/b>Hypoglycemia (1% or greater)<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Anemia (1% or greater), Aplastic anemia, Hemolytic anemia, Leukopenia (1% or greater), Pancytopenia, Thrombocytopenia (1% or greater), Thrombotic thrombocytopenic purpura<\/li><li><b>Hepatic:<\/b>Acute hepatitis, Hepatic failure, acute, Hepatic necrosis, Jaundice<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction, Vasculitis, Hypersensitivity (less than 1%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (less than 1%), Myasthenia gravis, Exacerbation, Rupture of tendon, Tendinitis<\/li><li><b>Neurologic:<\/b>Extrapyramidal disease, Exacerbation, Neurotoxicity, Peripheral neuropathy, Seizure (less than 1%)<\/li><li><b>Renal:<\/b>Acute renal failure, Interstitial nephritis, Renal impairment, acute<\/li><li><b>Respiratory:<\/b>Extrinsic allergic alveolitis<\/li><li><b>Other:<\/b>Angioedema (less than 1%), Fever (1% to 3%), Serum sickness due to drug<\/li><\/ul>"},{"id":"420450-s-6","title":"Drug Name Info","sub":{"0":{"id":"420450-s-6-17","title":"US Trade Names","mono":"<ul><li>Floxin<\/li><li>Ocuflox<\/li><\/ul>"},"2":{"id":"420450-s-6-19","title":"Class","mono":"<ul><li>Antibacterial<\/li><li>Antibiotic<\/li><li>Fluoroquinolone<\/li><\/ul>"},"3":{"id":"420450-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"420450-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"420450-s-7","title":"Mechanism Of Action","mono":"<ul><li>Ophthalmic: Ofloxacin's bactericidal action results from interference with the enzyme, DNA gyrase, which is needed for synthesis of bacterial DNA. <\/li><li>Otic: Bactericidal; ofloxacin acts intracellularly by inhibiting DNA gyrase. DNA gyrase is an essential bacterial enzyme that is a critical catalyst in the replication, transcription, deactivation, and repair of bacterial DNA. <\/li><\/ul>"},{"id":"420450-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"420450-s-8-26","title":"Excretion","mono":"Ophthalmic: Renal: unchanged  <br\/>"}}},{"id":"420450-s-9","title":"Administration","mono":"<ul><li><b>Ophthalmic<\/b><br\/>do not inject subconjunctivally or directly into the anterior chamber of the eye<br\/><\/li><li><b>Oral<\/b><br\/><ul><li>do not take within 2 hours before or after antacids, iron, multivitamins containing zinc, or didanosine<\/li><li>take with fluids<\/li><li>may be taken without regard to meals<\/li><\/ul><\/li><li><b>Otic<\/b><br\/>warm by hand for 1 to 2 min<br\/><\/li><\/ul>"},{"id":"420450-s-10","title":"Monitoring","mono":"fever, CBC, symptomatic improvement<br\/>"},{"id":"420450-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Ophthalmic Solution: 0.3 %<\/li><li>Oral Tablet: 200 MG, 300 MG, 400 MG<\/li><li>Otic Solution: 0.3 %<\/li><\/ul><\/li><li><b>Floxin<\/b><br\/><ul><li>Oral Tablet: 200 MG, 300 MG, 400 MG<\/li><li>Otic Solution: 0.3 %<\/li><\/ul><\/li><li><b>Ocuflox<\/b><br\/>Ophthalmic Solution: 0.3 %<br\/><\/li><\/ul>"},{"id":"420450-s-12","title":"Toxicology","sub":[{"id":"420450-s-12-31","title":"Clinical Effects","mono":"<b>FLUOROQUINOLONES<\/b><br\/>USES: Fluoroquinolones are bacteriocidal broad spectrum antibiotics. PHARMACOLOGY: Fluoroquinolones inhibit bacterial topoisomerase IV and DNA gyrase enzymes required for DNA replication, transcription, repair and recombination. EPIDEMIOLOGY: Overdose is rare. OVERDOSE: Dizziness, drowsiness, disorientation, slurred speech, nausea and vomiting. ADVERSE EFFECTS: Nausea\/vomiting, diarrhea, headache, drowsiness, and insomnia. Seizures, hallucinations, elevated liver enzymes and renal toxicity are rare. Seizures appear related to predisposing factors. Hypersensitivity reactions including anaphylaxis and vasculitis have developed. WITHDRAWAL FROM MARKET: Grepafloxacin was withdrawn from the worldwide market in October, 1999 after reports of cardiovascular toxicity; QT prolongation had been associated with its use. Gatifloxacin was voluntarily withdrawn from the market in May 2006 due to reports of severe hypo- and hyperglycemic events. <br\/>"},{"id":"420450-s-12-32","title":"Treatment","mono":"<b>FLUOROQUINOLONES <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: Activated charcoal, gastric lavage<\/li><li>Seizure: IV benzodiazepines, barbiturates<\/li><li>Monitoring of patient: Monitor liver enzymes and renal function with significant overdose.  Monitor fluid &amp; electrolyte status if severe GI effects; CNS function.<\/li><\/ul>"},{"id":"420450-s-12-33","title":"Range of Toxicity","mono":"<b>FLUOROQUINOLONES<\/b><br\/>Unknown.  Recommended dose (adults):  300-500 mg BID; contraindicated in children. <br\/>"}]},{"id":"420450-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to immediately report symptoms of tendonitis or tendon rupture (pain, swelling, inflammation of tendon), especially if elderly and\/or using concomitant steroids.<\/li><li>Tell patient to immediately report symptoms of peripheral neuropathy, including pain, burning, tingling, or numbness.<\/li><li>Advise patient to use sunscreen, avoid tanning beds, and avoid excessive exposure to sunlight as drug causes phototoxicity.<\/li><li>Counsel patient to avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness and lightheadedness.<\/li><li>Side effects may include nausea, vomiting, vaginitis, rash, headaches, confusion, restlessness, or insomnia.<\/li><li>Otic side effects may include taste perversion, earache, paresthesia, pruritus, vertigo, or rash.<\/li><li>Advise diabetic patient to monitor for symptoms of hyperglycemia or hypoglycemia and to report difficulties with glycemic control.<\/li><li>Instruct patient to immediately report severe diarrhea, dermatologic reactions (toxic epidermal necrolysis, Stevens-Johnson), or QT prolongation (palpitations, loss of consciousness).<\/li><li>Advise patient to immediately report CNS events (hallucinations, depression, suicidal thoughts, or convulsions).<\/li><li>Tell patient to maintain adequate hydration during therapy.<\/li><li>Advise patient to take drug 2 hours before or 2 hours after magnesium or aluminum-containing antacids or products containing calcium, iron, or zinc.<\/li><\/ul>"}]}